Nasdaq
$28.47▼ 0.11%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $951.8MShares out 33.4M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 5d agoAfter-hours26.10.20 05:108-KKey event#●●●#●●●
SpyGlass Pharma, Inc.Bullish
SpyGlass Pharma announced positive 4-year interim data from its first-in-human trial of the BIM-IOL System. Results from 21 evaluable patients showed a 37% reduction in mean intraocular pressure and 86% of patients remained off topical IOP-lowering drops with no product-related adverse events.…more
$28.47-0.11%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1Pre-market26.10.01 21:158-KKey event
SpyGlass Pharma, Inc.
On October 1, 2026, SpyGlass Pharma acquired Advanced Vision Science (AVS), a subsidiary of Santen Pharmaceutical, for approximately $13 million in cash. This acquisition secures scalable manufacturing capacity for the company's BIM-IOL system and accelerates its ability to expand into premium lens options.…more
$28.47-0.11%vs prev closeView filingShare - 8.6After-hours26.08.07 05:3710-QEarnings
SpyGlass Pharma, Inc.
스파이글래스 파마(SpyGlass Pharma)는 2026년 6월 30일 기준 분기 보고서(10-Q)를 제출하였으며, 2026년 7월 29일 기준 발행 주식 수는 33,447,979주입니다. 회사는 현재 임상 단계의 기업으로서 주요 제품 후보인 BIM-IOL 시스템의 개발 및 상업화를 추진 중이며, 재무 보고를 통해 내부 통제 약점 개선 및 운영 비용 관리 계획을 명시했습니다.…more
$28.47-0.11%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 21:00#●●●#●●●
SpyGlass Pharma Reports Positive 4-Year Data for BIM-IOL System
SpyGlass Pharma announced that its BIM-IOL system demonstrated sustained intraocular pressure reduction and safety in a 4-year first-in-human trial. While the results are promising, the company must still complete further clinical development and regulatory processes for commercial approval.…more
$28.47-0.11%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.1Pre-market26.10.01 21:00
●●●●●●●● ●●●●● ●●●●●●
SpyGlass Pharma has acquired ophthalmic medical device company AVS for approximately $13 million to secure scalable manufacturing capacity for its intraocular lenses. This acquisition aims to accelerate the production of its lens portfolio and support the commercialization of its drug delivery system.…more
$28.47-0.11%vs prev close - 9.2Pre-market26.09.02 21:00
●●●●●●●● ●●●●● ●●●●●●
SpyGlass Pharma announced that its management team will participate in several upcoming healthcare investor conferences throughout September. These events consist of corporate presentations and meetings, which are standard investor relations activities.…more
$28.47-0.11%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report